Regulatory News
Thursday, March 24, 2016
BRIEF-Biomarin- gets European orphan drug designation for Gene Therapy drug for Hemophilia A
* Receives European orphan drug designation for bmn 270,
first investigational aav-factor viii gene therapy for patients
with hemophilia a
Source text for Eikon:
Further company coverage:
Read more
No comments:
Post a Comment
Newer Post
Older Post
Home
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment